Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa

References

• Abu-Raddad, L.J., Chemaitelly, H., Yassine, H.M., et al. 2021. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. Journal of Travel Medicine. doi:https://doi.org/10.1093/jtm/taab083.
   Web of Science ®Google Scholar
• Africa CDC COVID-19 Dashboard. 2021. https://africacdc.org/covid-19/ (accessed 17 May 2021).
   Google Scholar
• Barouch, D.H., Stephenson, K.E., Sadoff, J., et al. 2021. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. New England Journal of Medicine 385: 951–953.
   PubMed Web of Science ®Google Scholar
• Bernal, J.L., Andrews, N., Gower, C., et al. 2021. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv 2021.05.22.21257658.
   Google Scholar
• Campbell, F., Archer, B., Laurenson-Schafer, H., et al. 2021. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin 26(24): 2100509. doi:https://doi.org/10.2807/1560-7917.ES.2021.26.24.2100509.
   PubMedGoogle Scholar
• CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variant. 2021. sarXiv: 2106.08106. https://cov-spectrum.ethz.ch/explore/South%20Africa/AllSamples/AllTimes (accessed 1 September 2021).
   Google Scholar
• COVID-19 Corona Virus South African Resource Portal. 2020. https://sacoronavirus.co.za/ (accessed 2 September 2020).
   Google Scholar
• Elliott, P., Haw, D., Wang, H., et al. 2021. REACT-1 Round 13 Final Report: Exponential Growth, High Prevalence of SARS-CoV-2 and Vaccine Effectiveness Associated with Delta Variant in England During May to July 2021. London, Imperial College. https://spiral.imperial.ac.uk/bitstream/10044/1/90800/2/react1_r13_final_preprint_final.pdf (accessed 1 September 2021).
   Google Scholar
• Fisman, D.N. & Tuite, A.R. 2021. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada, from December to July, 2021. medRxiv 2021.07.05.21260050.
   Google Scholar
• Huang, B., Dai, L., Wang, H., et al. 2021. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv preprint. https://doi.org/https://doi.org/10.1101/2021.02.01.429069.
   Google Scholar
• Jongeneelen, M., Kaszas, K., Veldman, D., et al. 2021. Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern. bioRxiv: the preprint server for biology. 2021.07.01.450707.
   Google Scholar
• Karim, F., Moosa, M., Gosnell, B., et al. 2021. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv 2021.06.03.21258228.
   Google Scholar
• Li, B., Deng, A., Li, K., et al. 2021. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv 2021.07.07.21260122.
   Google Scholar
• Liu, C., Ginn, H.M., Dejnirattisai, W., et al. 2021a. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184(16): 4220–4236.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Arase, N., Kishikawa, J.-I., et al. 2021b. The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines. bioRxiv: the preprint server for biology. 2021.08.22.457114.
   Google Scholar
• Madhi, S.A., Baillie, V., Cutland, C.L., et al. 2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine. doi:https://doi.org/10.1056/NEJMoa2102214.
   Web of Science ®Google Scholar
• Nasreen, S., He, S., Chung, H., et al. 2021. Effectiveness of COVID-19 vaccines against variants of concern, Canada. medRxiv 2021.06.28.21259420.
   Google Scholar
• Ong, S.W.X., Chiew, C.J., Ang, L.W., et al. 2021. Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 (Beta), and B.1.617.2 (Delta). Lancet. https://doi.org/http://doi.org/10.2139/ssrn.3861566.
   Google Scholar
• Pearson, C.A.B., Russell, T.M.R., Davies, N.G., et al. 2021. Estimates of Severity and Transmissibility of Novel South Africa SARS-CoV-2 Variant 501Y.V2. CMMID Repository. https://cmmid.github.io/topics/covid19/sa-novel-variant.html.
   Google Scholar
• Planas, D., Veyer, D., Baidaliuk, A., et al. 2021. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596(7871): 276–280.
   PubMed Web of Science ®Google Scholar
• Pouwels, K.B., Pritchard, E., Matthews, P.C., et al. 2021. Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv 2021.08.18.21262237.
   Google Scholar
• Pritchard, E., Matthews, P.C., Stoesser, N., et al. 2021. Impact of vaccination on new SARS-CoV-2 infections in the UK. medRxiv 2021.04.22.21255913.
   Google Scholar
• Public Health England. 2021. Risk Assessment for SARS-CoV-2 Variant: Delta (VOC-21APR-02, B.1.617.2) – 8 July2021. England, Public Health England. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1000661/8_July_2021_Risk_assessment_for_SARS-CoV-2_variant_DELTA_02.00-1.pdf (accessed 12 July 2021).
   Google Scholar
• Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. 2021. Public Health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397: 2461–2462.
   PubMed Web of Science ®Google Scholar
• Shen, X., Tang, H., McDanal, C., et al. 2021. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv: the preprint server for biology. 2021.01.27.428516.
   Google Scholar
• Stowe, J., Andrews, N., Gower, C., et al. 2021. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. PHE preprint.
   Google Scholar
• Tegally, H., Wilkinson, E., Giovanetti, M., et al. 2020. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv preprint. doi:https://doi.org/10.1101/2020.12.21.20248640.
   Google Scholar
• Truong, T.T., Ryutov, A., Pandey, U., et al. 2021. Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. medRxiv.
   Google Scholar
• Voysey, M., Clemens, S.A.C., Madhi, S.A., et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397: 99–111.
   PubMed Web of Science ®Google Scholar
• Wang, P., Casner, R.G., Nair, M.S., et al. 2021a. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. bioRxiv: the preprint server for biology. 2021.03.01.433466.
   Google Scholar
• Wang, P., Liu, L., Iketani, S., et al. 2021b. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv: the preprint server for biology. 2021.01.25.428137.
   Google Scholar
• Wibmer, C.K., Ayres, F., Hermanus, T., et al. 2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine. 27: 622–625.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2021. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed 12 July 2021).
   Google Scholar
• Wu, K., Werner, A.P., Moliva, J.I., et al. 2021. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv: the preprint server for biology.
   Google Scholar